The Prognostic Value of Baseline 18F-FDG PET/CT in Stage IV Non–Small Cell Lung Cancer Patients Receiving Osimertinib Treatment
Baseline PET/CT metabolic parameters before osimertinib treatment may help identify potential NSCLC patients who could derive clinical benefit, and baseline MTV of the primary tumor from 18 F-FDG PET/CT is a reliable prognostic indicator for PFS in stage IV NSCLC patients treated with osimertinib.
Authors
- Zhen-Peng Jiang
- Huimin Shan
- Wei Fan (ORCID: https://orcid.org/0000-0001-5418-1714)
- Kai-yu Lu
- Dan Shao (ORCID: https://orcid.org/0000-0002-9925-0936)
- Haoyu Zhu (ORCID: https://orcid.org/0000-0001-8722-4645)
- You Cheng (ORCID: https://orcid.org/0000-0002-9526-8629)
Institutions
- Sun Yat-sen University (CN)
- Guangzhou First People's Hospital (CN)
- Guangdong Academy of Medical Sciences (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangdong Provincial People's Hospital (CN)
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Clinical Nuclear Medicine
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1097/rlu.0000000000006039
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52